The Effect of Amantadine on Corneal Endothelium in Subjects with Parkinson's Disease

To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Endothelial indices we...

Full description

Saved in:
Bibliographic Details
Published inOphthalmology (Rochester, Minn.) Vol. 117; no. 6; pp. 1214 - 1219
Main Authors Chang, Ki Cheol, Jeong, Jin Ho, Kim, Mee Kum, Wee, Won Ryang, Lee, Jin Hak, Jeon, Beom Seok
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 01.06.2010
Elsevier
Subjects
Online AccessGet full text
ISSN0161-6420
1549-4713
1549-4713
DOI10.1016/j.ophtha.2009.10.039

Cover

Abstract To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89, P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87, P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD ( P<0.05) compared with the normal age-matched control group. Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
AbstractList To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89, P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87, P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD ( P<0.05) compared with the normal age-matched control group. Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Objective To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Design Cross-sectional study. Participants A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Methods Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Main Outcome Measures Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. Results The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89, P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87, P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD ( P <0.05) compared with the normal age-matched control group. Conclusions Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.
To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.OBJECTIVETo evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.Cross-sectional study.DESIGNCross-sectional study.A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.PARTICIPANTSA total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.METHODSEndothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.MAIN OUTCOME MEASURESSlit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.The amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group.RESULTSThe amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group.Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.CONCLUSIONSAmantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.
To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. The amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group. Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.
Author Chang, Ki Cheol
Lee, Jin Hak
Wee, Won Ryang
Kim, Mee Kum
Jeong, Jin Ho
Jeon, Beom Seok
Author_xml – sequence: 1
  givenname: Ki Cheol
  surname: Chang
  fullname: Chang, Ki Cheol
  organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
– sequence: 2
  givenname: Jin Ho
  surname: Jeong
  fullname: Jeong, Jin Ho
  organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
– sequence: 3
  givenname: Mee Kum
  surname: Kim
  fullname: Kim, Mee Kum
  organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
– sequence: 4
  givenname: Won Ryang
  surname: Wee
  fullname: Wee, Won Ryang
  email: wrwee@snu.ac.kr
  organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
– sequence: 5
  givenname: Jin Hak
  surname: Lee
  fullname: Lee, Jin Hak
  organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea
– sequence: 6
  givenname: Beom Seok
  surname: Jeon
  fullname: Jeon, Beom Seok
  organization: Department of Neurology, Seoul National University College of Medicine, Seoul, Korea
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22879951$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20153901$$D View this record in MEDLINE/PubMed
BookMark eNqVkl9rFDEUxYO02G31G4jkRfo022Qy_yIilHW1hYJC1-eQSe4wmc4ka5JR-u3NsKuCIMWncC-_c5Occ8_RiXUWEHpFyZoSWl0Na7fvYy_XOSE8tdaE8WdoRcuCZ0VN2QlaJYxmVZGTM3QewkAIqSpWPEdnOaEl44Su0G7XA952HaiIXYevJ2mj1MYCdhZvnLcgR7y12sUeRjNP2Fh8P7dD4gP-YWKPv0j_YGxw9jLgDyaADPACnXZyDPDyeF6grx-3u81Ndvf50-3m-i5TBecxY6UiWudKpye2sgMm66olrNNVSTk0UOqcsyKVtAQtuZKpboqm1FDUqmMtu0CXh7l7777NEKKYTFAwjtKCm4OoGaNNyWieyNdHcm4n0GLvzST9o_hlRALeHAEZlBw7L60y4Q-XNzXn5cIVB055F4KH7jdCiVhyEYM45CKWXJZuyiXJ3v4lUybKaJyNXprxKfH7gxiSl98NeBGUAatAG59yENqZ_x2gRmNN-ucDPEIY3OxtyklQEXJBxP2yN8vakORMXvPFvnf_HvD0_T8B3u7T6g
CODEN OPHTDG
CitedBy_id crossref_primary_10_1016_j_baga_2013_09_001
crossref_primary_10_1016_j_jcjo_2013_12_010
crossref_primary_10_1016_j_pmrj_2018_03_007
crossref_primary_10_1097_ICO_0000000000001951
crossref_primary_10_1007_s00702_018_1869_1
crossref_primary_10_52725_aocl_2024_23_2_76
crossref_primary_10_1097_ICO_0b013e31823f8af4
crossref_primary_10_1016_j_ajo_2021_05_020
crossref_primary_10_1186_s12886_022_02410_1
crossref_primary_10_1016_j_oftal_2011_09_007
crossref_primary_10_1016_j_exer_2019_02_010
crossref_primary_10_1016_j_ajo_2016_08_034
crossref_primary_10_1016_j_oftale_2011_09_005
crossref_primary_10_15446_revfacmed_v65n3_56637
crossref_primary_10_4103_IJO_IJO_1149_23
crossref_primary_10_1038_s41433_019_0497_9
crossref_primary_10_3389_fneur_2023_1236366
crossref_primary_10_1016_j_ajoc_2020_100852
crossref_primary_10_3390_life12122141
crossref_primary_10_1016_j_exer_2024_110225
crossref_primary_10_1080_00207454_2020_1761353
crossref_primary_10_1016_j_ajoc_2023_101881
crossref_primary_10_14802_jmd_13008
crossref_primary_10_17116_jnevro2021121041101
Cites_doi 10.1097/01.ico.0000130417.91438.7e
10.1016/0002-9394(84)90120-X
10.1002/mds.22136
10.1097/00003226-199004000-00017
10.1212/WNL.25.8.695
10.1007/BF00839973
10.1016/j.ophtha.2008.03.011
10.1097/ICO.0b013e3181450d4c
10.1111/j.1468-1331.2005.01025.x
10.1212/WNL.50.5.1323
10.1097/ICO.0b013e318180e526
10.1007/s004170000223
10.1001/jama.237.12.1200a
10.1016/j.parkreldis.2007.03.003
10.1016/0002-9394(86)90209-6
10.1097/ICO.0b013e318033a6da
10.1016/S0002-9394(14)76952-1
ContentType Journal Article
Copyright 2010 American Academy of Ophthalmology
American Academy of Ophthalmology
2015 INIST-CNRS
Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2010 American Academy of Ophthalmology
– notice: American Academy of Ophthalmology
– notice: 2015 INIST-CNRS
– notice: Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.ophtha.2009.10.039
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList


MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1549-4713
EndPage 1219
ExternalDocumentID 20153901
22879951
10_1016_j_ophtha_2009_10_039
S0161642009012792
1_s2_0_S0161642009012792
Genre Journal Article
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
123
1B1
1CY
1P~
1~5
29N
4.4
457
4G.
53G
5RE
5VS
7-5
71M
AAEDT
AAEDW
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
ABCQX
ABFRF
ABJNI
ABLJU
ABMAC
ABOCM
ABWVN
ACGFO
ACGFS
ACIUM
ACNCT
ACRPL
ACVFH
ADCNI
ADMUD
ADNMO
AEFWE
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AGCQF
AGQPQ
AIGII
AITUG
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BELOY
C5W
CS3
DU5
EBS
EFJIC
EFKBS
EJD
F5P
FDB
FEDTE
FGOYB
GBLVA
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
M27
M41
MO0
N4W
N9A
NQ-
O9-
OF-
OPF
OQ~
P2P
R2-
ROL
RPZ
SDG
SEL
SES
SSZ
UHS
UNMZH
UV1
WH7
X7M
XH2
XPP
Z5R
ZGI
ZXP
ADPAM
RIG
AAIAV
AGZHU
AHPSJ
ALXNB
ZA5
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c499t-35c0dd2cd642bafe3a76b03fd6519e8e5d2934fd615eda9cad298485de47cf3b3
ISSN 0161-6420
1549-4713
IngestDate Sun Sep 28 10:28:09 EDT 2025
Mon Jul 21 05:59:13 EDT 2025
Mon Jul 21 09:14:09 EDT 2025
Tue Jul 01 01:01:31 EDT 2025
Thu Apr 24 23:07:36 EDT 2025
Fri Feb 23 02:17:05 EST 2024
Sun Feb 23 10:19:56 EST 2025
Tue Aug 26 19:02:59 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Human
Agonist
Nervous system diseases
Amantadine
Cornea
Dopamine receptor
Parkinson disease
Glutamate receptor
Antiparkinson agent
Cerebral disorder
Endothelium
Amantadine derivatives
Central nervous system disease
Dopamine agonist
Antiviral
Degenerative disease
Antagonist
Ophthalmology
NMDA receptor
Extrapyramidal syndrome
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c499t-35c0dd2cd642bafe3a76b03fd6519e8e5d2934fd615eda9cad298485de47cf3b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20153901
PQID 733185312
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_733185312
pubmed_primary_20153901
pascalfrancis_primary_22879951
crossref_primary_10_1016_j_ophtha_2009_10_039
crossref_citationtrail_10_1016_j_ophtha_2009_10_039
elsevier_sciencedirect_doi_10_1016_j_ophtha_2009_10_039
elsevier_clinicalkeyesjournals_1_s2_0_S0161642009012792
elsevier_clinicalkey_doi_10_1016_j_ophtha_2009_10_039
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-06-01
PublicationDateYYYYMMDD 2010-06-01
PublicationDate_xml – month: 06
  year: 2010
  text: 2010-06-01
  day: 01
PublicationDecade 2010
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: United States
PublicationTitle Ophthalmology (Rochester, Minn.)
PublicationTitleAlternate Ophthalmology
PublicationYear 2010
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Pearlman, Kadish, Ramseyer (bib1) 1977; 237
Fraunfelder, Meyer (bib3) 1990; 110
Lee, Park, Lee (bib17) 2001; 239
Mac Rae, Matsuda, Shellans, Rich (bib16) 1986; 102
Sheng, Bullimore (bib15) 2007; 26
Jeng, Galor, Lee (bib7) 2008; 115
French, Margo (bib14) 2007; 26
Chang, Kim, Wee, Lee (bib8) 2008; 27
Nogaki, Morimatsu (bib4) 1993; 240
Kubo, Iwatake, Ebihara (bib6) 2008; 14
Ray, O'Day (bib11) 1985; 26
Schultz, Matsuda, Yee (bib18) 1984; 98
Hughes, Feiz, Flynn, Brodsky (bib5) 2004; 23
Dubow, Rezak, Berman (bib9) 2008; 23
Hadjikoutis, Morgan, Wild, Smith (bib10) 2005; 12
Fahn, Isgreen (bib12) 1975; 25
Verhagen Metman, Del Potto, van den Munckhof (bib13) 1998; 50
Blanchard (bib2) 1990; 9
Nogaki (10.1016/j.ophtha.2009.10.039_bib4) 1993; 240
Hadjikoutis (10.1016/j.ophtha.2009.10.039_bib10) 2005; 12
Fahn (10.1016/j.ophtha.2009.10.039_bib12) 1975; 25
Kubo (10.1016/j.ophtha.2009.10.039_bib6) 2008; 14
Schultz (10.1016/j.ophtha.2009.10.039_bib18) 1984; 98
Chang (10.1016/j.ophtha.2009.10.039_bib8) 2008; 27
Dubow (10.1016/j.ophtha.2009.10.039_bib9) 2008; 23
Blanchard (10.1016/j.ophtha.2009.10.039_bib2) 1990; 9
Fraunfelder (10.1016/j.ophtha.2009.10.039_bib3) 1990; 110
Verhagen Metman (10.1016/j.ophtha.2009.10.039_bib13) 1998; 50
Mac Rae (10.1016/j.ophtha.2009.10.039_bib16) 1986; 102
Hughes (10.1016/j.ophtha.2009.10.039_bib5) 2004; 23
Sheng (10.1016/j.ophtha.2009.10.039_bib15) 2007; 26
Jeng (10.1016/j.ophtha.2009.10.039_bib7) 2008; 115
Ray (10.1016/j.ophtha.2009.10.039_bib11) 1985; 26
French (10.1016/j.ophtha.2009.10.039_bib14) 2007; 26
Lee (10.1016/j.ophtha.2009.10.039_bib17) 2001; 239
Pearlman (10.1016/j.ophtha.2009.10.039_bib1) 1977; 237
References_xml – volume: 102
  start-page: 50
  year: 1986
  end-page: 57
  ident: bib16
  article-title: The effects of hard and soft contact lenses on the corneal endothelium
  publication-title: Am J Ophthalmol
– volume: 23
  start-page: 823
  year: 2004
  end-page: 824
  ident: bib5
  article-title: Reversible amantadine-induced corneal edema in an adolescent
  publication-title: Cornea
– volume: 26
  start-page: 1087
  year: 2007
  end-page: 1089
  ident: bib14
  article-title: Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration
  publication-title: Cornea
– volume: 239
  start-page: 1
  year: 2001
  end-page: 4
  ident: bib17
  article-title: A comparative study of corneal endothelial changes induced by different durations of soft contact lens wear
  publication-title: Graefes Arch Clin Exp Ophthalmol
– volume: 237
  start-page: 1200
  year: 1977
  ident: bib1
  article-title: Vision loss associated with amantadine hydrochloride use [letter]
  publication-title: JAMA
– volume: 115
  start-page: 1540
  year: 2008
  end-page: 1544
  ident: bib7
  article-title: Amantadine-associated corneal edema: potentially irreversible even after cessation of the medication
  publication-title: Ophthalmology
– volume: 23
  start-page: 2096
  year: 2008
  end-page: 2097
  ident: bib9
  article-title: Reversible corneal edema associated with amantadine use: an unrecognized problem [letter]
  publication-title: Mov Disord
– volume: 50
  start-page: 1323
  year: 1998
  end-page: 1326
  ident: bib13
  article-title: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
  publication-title: Neurology
– volume: 14
  start-page: 166
  year: 2008
  end-page: 169
  ident: bib6
  article-title: Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature
  publication-title: Parkinsonism Relat Disord
– volume: 26
  start-page: 520
  year: 2007
  end-page: 525
  ident: bib15
  article-title: Factors affecting corneal endothelial morphology
  publication-title: Cornea
– volume: 110
  start-page: 96
  year: 1990
  end-page: 97
  ident: bib3
  article-title: Amantadine and corneal deposits
  publication-title: Am J Ophthalmol
– volume: 12
  start-page: 499
  year: 2005
  end-page: 507
  ident: bib10
  article-title: Ocular complications of neurological therapy
  publication-title: Eur J Neurol
– volume: 9
  start-page: 181
  year: 1990
  ident: bib2
  article-title: Amantadine caused corneal edema [letter]
  publication-title: Cornea
– volume: 240
  start-page: 388
  year: 1993
  end-page: 389
  ident: bib4
  article-title: Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride [letter]
  publication-title: J Neurol
– volume: 27
  start-page: 1182
  year: 2008
  end-page: 1185
  ident: bib8
  article-title: Corneal endothelial dysfunction associated with amantadine toxicity
  publication-title: Cornea
– volume: 25
  start-page: 695
  year: 1975
  end-page: 700
  ident: bib12
  article-title: Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses
  publication-title: Neurology
– volume: 26
  start-page: 1186
  year: 1985
  end-page: 1188
  ident: bib11
  article-title: Statistical analysis of multi-eye data in ophthalmic research
  publication-title: Invest Ophthalmol Vis Sci
– volume: 98
  start-page: 401
  year: 1984
  end-page: 410
  ident: bib18
  article-title: Corneal endothelial changes in type I and type II diabetes mellitus
  publication-title: Am J Ophthalmol
– volume: 23
  start-page: 823
  year: 2004
  ident: 10.1016/j.ophtha.2009.10.039_bib5
  article-title: Reversible amantadine-induced corneal edema in an adolescent
  publication-title: Cornea
  doi: 10.1097/01.ico.0000130417.91438.7e
– volume: 98
  start-page: 401
  year: 1984
  ident: 10.1016/j.ophtha.2009.10.039_bib18
  article-title: Corneal endothelial changes in type I and type II diabetes mellitus
  publication-title: Am J Ophthalmol
  doi: 10.1016/0002-9394(84)90120-X
– volume: 23
  start-page: 2096
  year: 2008
  ident: 10.1016/j.ophtha.2009.10.039_bib9
  article-title: Reversible corneal edema associated with amantadine use: an unrecognized problem [letter]
  publication-title: Mov Disord
  doi: 10.1002/mds.22136
– volume: 9
  start-page: 181
  year: 1990
  ident: 10.1016/j.ophtha.2009.10.039_bib2
  article-title: Amantadine caused corneal edema [letter]
  publication-title: Cornea
  doi: 10.1097/00003226-199004000-00017
– volume: 26
  start-page: 1186
  year: 1985
  ident: 10.1016/j.ophtha.2009.10.039_bib11
  article-title: Statistical analysis of multi-eye data in ophthalmic research
  publication-title: Invest Ophthalmol Vis Sci
– volume: 25
  start-page: 695
  year: 1975
  ident: 10.1016/j.ophtha.2009.10.039_bib12
  article-title: Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses
  publication-title: Neurology
  doi: 10.1212/WNL.25.8.695
– volume: 240
  start-page: 388
  year: 1993
  ident: 10.1016/j.ophtha.2009.10.039_bib4
  article-title: Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride [letter]
  publication-title: J Neurol
  doi: 10.1007/BF00839973
– volume: 115
  start-page: 1540
  year: 2008
  ident: 10.1016/j.ophtha.2009.10.039_bib7
  article-title: Amantadine-associated corneal edema: potentially irreversible even after cessation of the medication
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2008.03.011
– volume: 26
  start-page: 1087
  year: 2007
  ident: 10.1016/j.ophtha.2009.10.039_bib14
  article-title: Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration
  publication-title: Cornea
  doi: 10.1097/ICO.0b013e3181450d4c
– volume: 12
  start-page: 499
  year: 2005
  ident: 10.1016/j.ophtha.2009.10.039_bib10
  article-title: Ocular complications of neurological therapy
  publication-title: Eur J Neurol
  doi: 10.1111/j.1468-1331.2005.01025.x
– volume: 50
  start-page: 1323
  year: 1998
  ident: 10.1016/j.ophtha.2009.10.039_bib13
  article-title: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
  publication-title: Neurology
  doi: 10.1212/WNL.50.5.1323
– volume: 27
  start-page: 1182
  year: 2008
  ident: 10.1016/j.ophtha.2009.10.039_bib8
  article-title: Corneal endothelial dysfunction associated with amantadine toxicity
  publication-title: Cornea
  doi: 10.1097/ICO.0b013e318180e526
– volume: 239
  start-page: 1
  year: 2001
  ident: 10.1016/j.ophtha.2009.10.039_bib17
  article-title: A comparative study of corneal endothelial changes induced by different durations of soft contact lens wear
  publication-title: Graefes Arch Clin Exp Ophthalmol
  doi: 10.1007/s004170000223
– volume: 237
  start-page: 1200
  year: 1977
  ident: 10.1016/j.ophtha.2009.10.039_bib1
  article-title: Vision loss associated with amantadine hydrochloride use [letter]
  publication-title: JAMA
  doi: 10.1001/jama.237.12.1200a
– volume: 14
  start-page: 166
  year: 2008
  ident: 10.1016/j.ophtha.2009.10.039_bib6
  article-title: Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature
  publication-title: Parkinsonism Relat Disord
  doi: 10.1016/j.parkreldis.2007.03.003
– volume: 102
  start-page: 50
  year: 1986
  ident: 10.1016/j.ophtha.2009.10.039_bib16
  article-title: The effects of hard and soft contact lenses on the corneal endothelium
  publication-title: Am J Ophthalmol
  doi: 10.1016/0002-9394(86)90209-6
– volume: 26
  start-page: 520
  year: 2007
  ident: 10.1016/j.ophtha.2009.10.039_bib15
  article-title: Factors affecting corneal endothelial morphology
  publication-title: Cornea
  doi: 10.1097/ICO.0b013e318033a6da
– volume: 110
  start-page: 96
  year: 1990
  ident: 10.1016/j.ophtha.2009.10.039_bib3
  article-title: Amantadine and corneal deposits
  publication-title: Am J Ophthalmol
  doi: 10.1016/S0002-9394(14)76952-1
SSID ssj0006634
Score 2.1282
Snippet To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169...
Objective To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Design Cross-sectional study. Participants A...
To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.OBJECTIVETo evaluate the effect of amantadine on corneal...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1214
SubjectTerms Adult
Aged
Amantadine - adverse effects
Antiparkinson Agents - adverse effects
Biological and medical sciences
Cell Count
Corneal Diseases - chemically induced
Corneal Diseases - pathology
Cross-Sectional Studies
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dose-Response Relationship, Drug
Endothelium, Corneal - drug effects
Endothelium, Corneal - pathology
Female
Humans
Male
Medical sciences
Middle Aged
Miscellaneous
Nervous system (semeiology, syndromes)
Nervous system as a whole
Neurology
Ophthalmology
Parkinson Disease - drug therapy
Title The Effect of Amantadine on Corneal Endothelium in Subjects with Parkinson's Disease
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0161642009012792
https://www.clinicalkey.es/playcontent/1-s2.0-S0161642009012792
https://dx.doi.org/10.1016/j.ophtha.2009.10.039
https://www.ncbi.nlm.nih.gov/pubmed/20153901
https://www.proquest.com/docview/733185312
Volume 117
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1549-4713
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0006634
  issn: 0161-6420
  databaseCode: AKRWK
  dateStart: 19930801
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmMwxu7LLkUPgz0UBd8vjyXrKA3ZoEtJ34RiySQhsUOdPGw_b79s51iSkywN7fpiYkeyLZ3P0tHRd84h5HMOk2aSxQ4LRZKxQDohS_3MZ0Ee5n4sgtQXNdvie3R-FVxch9et1p8t1tJ6Ne5mv2_1K3mIVOEayBW9ZP9Dss1N4QL8BvnCESQMx3vL2IQfRoVyAb2ElHiFOwC98qaogwYXEp2s5tP1Am0bMFDMagJHbYBFn2fj_hVXGImz2awx-uqP5WQ1EfOFjtRUmxtMhi3NuS-K7pYtoWetz_3pSW-idPKuQcMpvlCW_4sBtsrdP01a54FSJ32de3nwVVt8miIjTRoaQesuf5kn7RYy5gvcebc0K2vRjFwGiyBnZ0jW_pwGe9sDrOtpn1MzWbtmwN2bCLRNYtYt627ScUmRxacjJ-3G3T7r9V1WeV2H_cS3wZdxUtyS11n6_onH7fLK4w7fK_qIHHlxFHltcnTavxz1G30AdDoTYV431Dpw1izD_fc7pCA9XYoKPttc51s5vCCqFaPhc_LMrGjoqYbnC9JSxUvyeGA4G6_IEFBKNUppmdMNSmlZUINSuoVSOi2oRSlFlNIGpV8qajD6mlx9Oxv2zpnJ5cEyWFOvmB9mjpReJqEHxiJXvoijsePnMoIlhEpUKEHvDODUDZUUaSbgPAmSUKogznJ_7L8h7aIs1DtCQYHFnAOuE-cycDyVShfmkTxOc4EOo2GH-LYDeWYC3WO-lTm3jMYZ192OOVhTvArd3iGsqbXUgV7uKB9a2XDrxAzTLgcA3lEvvq2eqsy4UvFDANuuadRjrfbe45nHO-BpGuh5CQaEdDuEWjRxmF5wz1AUqlxXHFO6gkbvwtPfapRtKoMg0GL6_sEt-kCebIaEj6S9ulmrT6Djr8bH5iP6C_Vq8Xw
linkProvider Library Specific Holdings
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Effect+of+Amantadine+on+Corneal+Endothelium+in+Subjects+with+Parkinson%27s+Disease&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Chang%2C+Ki+Cheol%2C+MD&rft.au=Jeong%2C+Jin+Ho%2C+MD&rft.au=Kim%2C+Mee+Kum%2C+MD%2C+PhD&rft.au=Wee%2C+Won+Ryang%2C+MD%2C+PhD&rft.date=2010-06-01&rft.issn=0161-6420&rft.volume=117&rft.issue=6&rft.spage=1214&rft.epage=1219&rft_id=info:doi/10.1016%2Fj.ophtha.2009.10.039&rft.externalDBID=ECK1-s2.0-S0161642009012792&rft.externalDocID=1_s2_0_S0161642009012792
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642009X00199%2Fcov150h.gif